Novavax Inc stock (US6707721049): shares trade around USD 10 after recent volatility and licensing focus

Novavax shares on Nasdaq continue to trade around the 10 dollar mark after a volatile month, as the US vaccine maker pursues a licensing-focused strategy and investors digest updated demand assumptions for its protein-based COVID-19 shot.

Novavax shares on the Nasdaq Stock Market were quoted around USD 10 in recent sessions, leaving the US biotechnology company with a market capitalization of about USD 1.8 billion as investors reassess its licensing strategy and updated demand expectations for its COVID-19 vaccine portfolio, according to data from Stock Analysis as of 05/28/2026 and Robinhood as of 05/27/2026.

The stock, which trades under the ticker NVAX in the United States, has seen pronounced swings in recent weeks as markets weigh the companys transition from a primarily direct-sales approach toward a model that leans more heavily on partnerships and out-licensing of its protein-based vaccine technology, as highlighted in a recent narrative on Simply Wall St discussing confidence in licensing shifts and partnerships.

For investors following the home-country market, the United States remains the key reference point, with NVAX listed on Nasdaq and subject to oversight by the US Securities and Exchange Commission, while trading volumes and price action on secondary European venues such as Tradegate in Germany typically mirror US moves rather than drive them.

According to a Robinhood price quote updated on 05/27/2026, Novavax shares changed hands at about USD 10.34, while Stock Analysis indicated a market capitalization of roughly USD 1.82 billion on 05/28/2026, reflecting a sizeable increase over the past year as confidence around the companys ability to monetize its vaccine technology has improved.

In the background, the company has spent the past quarters working through earlier liquidity and going-concern worries by cutting costs, renegotiating supply contracts and shifting toward royalty-bearing arrangements with commercial partners, which has started to reshape investor perceptions of the risk profile even as questions remain about medium-term revenue visibility.

As of: 05/29/2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: Novavax Inc
• Sector/industry: Biotechnology - vaccines
• Headquarters/country: Gaithersburg, United States
• Core markets: United States, Europe, Asia-Pacific
• Key revenue drivers: COVID-19 vaccine franchise and related licensing agreements
• Home exchange/listing venue: Nasdaq (NVAX)
• Trading currency: USD

Novavax Inc: core business model

Novavax focuses on developing and commercializing protein-based vaccines with a growing emphasis on generating income from regional partnerships and licensing arrangements rather than relying solely on direct product sales.

Valuation metrics and multiples for Novavax Inc

With a market capitalization of about USD 1.82 billion as of 05/28/2026, Novavax sits in the mid-cap segment of the US biotech universe, according to Stock Analysis, reflecting an increase of more than 70 percent over the past year as the share price recovered from prior lows.

Traditional valuation multiples such as the price-earnings ratio remain of limited use for the stock, with Robinhood citing a negative P/E ratio of roughly -18.6 as of 05/27/2026, underscoring that investors are still primarily pricing Novavax on expectations of future profitability from its vaccine pipeline and licensing revenues rather than current earnings.

Conclusion

Novavax shares continue to trade around the 10 dollar mark on Nasdaq, leaving the US-based vaccine specialist in the mid-cap bracket as markets digest its shifting focus toward licensing-driven revenues.

Against this backdrop, valuation metrics such as the negative price-earnings ratio highlight that expectations for future earnings and the sustainability of partnership income streams remain central to how investors approach the stock.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.